Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Melanoma 5Uveal Melanoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Peripheral Blood Stem Cell Transplantation 14Mycophenolic Acid 9Cyclosporine 9fludarabine phosphate 8Tacrolimus 7Methotrexate 6Cyclophosphamide 5Busulfan 5Whole-Body Irradiation 4Radiotherapy 4Filgrastim 4Melphalan 3Imatinib Mesylate 3nilotinib 2aldesleukin 2Thiotepa 2Stem Cell Transplantation 2Flow Cytometry 2Decitabine 2Cord Blood Stem Cell Transplantation 2Blood Specimen Collection 2Antilymphocyte Serum 2Alemtuzumab 2sargramostim 1ruxolitinib 1ponatinib 1montanide ISA 51 1liposomal doxorubicin 1fludarabine 1ethanolamine oleate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid, Accelerated Phase × montanide ISA 51 × Clear all
NCT00004918 2013-01-07

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1/2 Completed
69 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡